Anti-depressants and Suicide
Does drug treatment for depression with selective serotonin reuptake inhibitors (SSRIs) increase or decrease the risk of completed suicide? The question is important in part because of recent government warnings that question the safety of SSRIs, one of the most widely prescribed medications in the world. While there are plausible clinical and behavioral arguments that SSRIs could have either positive or negative effects on suicide, randomized clinical trials have not been very informative because of small samples and other problems. In this paper we use data from 26 countries for up to 25 years to estimate the effect of SSRI sales on suicide mortality using just the variation in SSRI sales that can be explained by cross-country variation in the growth of drug sales more generally. We find that an increase in SSRI sales of 1 pill per capita (about a 12 percent increase over 2000 sales levels) is associated with a decline in suicide mortality of around 5 percent. These estimates imply a cost per statistical life far below most other government interventions to improve health outcomes.
-
-
Copy CitationJens Ludwig, Dave E. Marcotte, and Karen Norberg, "Anti-depressants and Suicide," NBER Working Paper 12906 (2007), https://doi.org/10.3386/w12906.Download Citation
Non-Technical Summaries
- An increase in SSRI sales of one pill per person per year -- about a 12 percent increase over year 2000 sales levels -- is associated...
Published Versions
Ludwig, Jens & Marcotte, Dave E. & Norberg, Karen, 2009.
"Anti-depressants and suicide,"
Journal of Health Economics,
Elsevier, vol. 28(3), pages 659-676, May.
citation courtesy of 
Related
Programs
More from the NBER
In addition to working papers, the NBER disseminates affiliates’ latest findings through a range of free periodicals — the NBER Reporter, the NBER Digest, the Bulletin on Health, and the Bulletin on Entrepreneurship — as well as online conference reports, video lectures, and interviews.
